One surprising fact in DBS technology is that the human deep brain stimulation (DBS) leads and the four shiny and tiny contacts on them have surprisingly not significantly changed for the last two decades. One reason for the durability of DBS lead design has been the long-term beneficial effects of utilizing this simple approach. There are however, compelling reasons to introduce new DBS lead designs into clinical practice.
National Parkinson Foundation's blog
Finding the right exercise program is extremely important for PD which is characterized by movement disorders such as slow or shuffling walk, tremors in the hands, fingers, forearms, feet, mouth, or chin, rigid or stiff muscles, including muscles that suddenly freeze for no reason, muscle pain and unsteady gait and balance.
Recently there has been a surge of interest in cholesterol and cholesterol lowering drugs (statins) and the risk of developing Parkinson’s disease (PD). Patients and families with a personal interest in the outcomes of these studies simply want to know whether they should consider starting a statin medication or they should change their diet. In this month's What’s Hot column we will examine the evidence and offer a recommendation for those considering a statin drug.
One of the common dreams shared by Parkinson’s disease patients around the globe is the possibility of living a pill free existence, and one year ago we shared the news of a therapy coming to the United States with the possibility to make this a reality for a select group of patients. This month we will update the previous blog post from 2014, and bring to you all of the information you need to know about the therapy. The therapy has received a full FDA approval and
The What’s Hot in Parkinson’s disease blog written in April 2013 featured a new extended release dopamine drug called IPX066. This new dopamine formulation achieved full FDA approval in January 2015. The drug is now sold under the name Rytary. At the Parkinson's Foundation we frequently hear from people with Parkinson’s disease (PD) that current carbidopa/levodopa medication preparations fail to adequately address disease-related symptoms.
Lewy body dementia (LBD) is a common progressive brain disease that affects thinking, movement, behavior and sleep. Approximately 1.3 million Americans have Lewy body dementia, but may not be correctly diagnosed because many doctors are unfamiliar with it. Most people see multiple doctors before receiving the final diagnosis of Lewy body dementia. Their first response is often, “Lewy what?”
Considerable evidence has been mounting supporting a relationship between the gastrointestinal system and Parkinson’s disease. Many pathologists and neurologists believe that Parkinson’s disease may start in the gut, however this view remains speculative. Additionally, there are many GI symptoms such as constipation that occur as prominent and disabling features of Parkinson’s disease.
In September 2012, the What’s Hot in Parkinson’s Disease? blog featured a new therapy that at that time had entered into human testing. The Austrian company AFFiRiS A.G. launched a two-year long clinical trial of a vaccine designed to stop Parkinson’s disease progression. In this month’s What’s Hot Column we will bring you an update on the vaccine and an update on another therapy (monoclonal antibodies) for the treatment of Parkinson’s disease.
Impulse control disorders including behaviors such as gambling, shopping, pathological eating and hypersexuality can occur in 1 out of every 6 people with Parkinson’s disease (PD) taking a dopamine agonist drug.
There has been speculation that migraine headache syndromes may have an important relationship to Parkinson’s disease. Though most associations uncovered by research studies have been speculative, two interesting papers appeared in the literature in the past few months, and investigators around the world have now rekindled the question, could headaches be related to Parkinson’s disease?